research Olumiant® (Baricitinib)-A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata.
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
Search
for
Sort by
Research
660-690 / 1000+ results research Selective delivery of adapalene to the human hair follicle under finite dose conditions using polymeric micelle nanocarriers
Polymeric micelle nanocarriers deliver adapalene more effectively to hair follicles than commercial products.
research Comparison of Different Alpha-blocker Combinations in Male Hypertensives with Refractory Lower Urinary Tract Symptoms
The doxazosin plus tamsulosin combination improved symptoms effectively with fewer side effects.
research Dual aspects of B cells in tumor immunity; B cells are capable of positive and negative regulation for tumor immunity against B16 melanoma
B cells can both help and hinder the body's defense against melanoma.
research Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata
Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
research Discovery of an Androgen Receptor Degrader Featuring a Pyridazinyl Glutarimide CRBN-Binding Motif for Transdermal Treatment of Androgenetic Alopecia
dAR-6–1 is a promising new treatment for hair loss that works better than minoxidil.
research The effect of the combined drug Yuperio with bisoprolol on the dynamics of the heart with dilation of the left chambers, the development of which is due to non-compactness of the myocardium of the left ventricle
Yuperio combined with bisoprolol improves heart function in patients with dilated cardiomyopathy.
research 27604 Response to baricitinib in the treatment of patients with early and late onset alopecia areata in the phase 2 portion of BRAVE-AA1 randomized controlled trial
Baricitinib was effective in treating both early and late onset alopecia areata.
research Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study
Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.
research LOP12
Sentinel lymph node biopsy is recommended for all types of desmoplastic melanoma due to higher rates of nodal metastasis.
research LOP12
Sentinel lymph node biopsy is recommended for all types of desmoplastic melanoma due to higher rates of nodal metastasis.
research Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis
Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.
research Lenalidomide Augments Differentiation of Cultured Hair Follicle Derived Melanocyte Stem Cells Into Functional Melanocytes
Lenalidomide helps hair follicle stem cells turn into melanocytes, which may improve repigmentation in vitiligo.
research Pharmacodynamics and pharmacokinetics of P-3074, a new finasteride topical solution, administered at four different doses
P-3074 effectively blocks scalp DHT better than oral finasteride.
research CD10 immunohistochemistry in prurigo nodularis
research Preclinical Development and Phase I Study of ZSYY001 , a Polymeric Micellar Paclitaxel for Advanced Solid Tumor
ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.
research Primary Vitreoretinal Lymphoma Presenting Solely with Asymptomatic Peripheral Drusenoid Lesions
Older patients with new retinal lesions may have cancer, and local radiation might not stop it from spreading.
research A case of recurrent acute pancreatitis following ocrelizumab use
Ocrelizumab may cause pancreatitis in some patients.
research MP13-07 FINASTERIDE MONOTHERAPY BEFORE TURP: SIGNIFICANT IMPROVEMENT IN EARLY POSTOPERATIVE QUALITY OF LIFE
Finasteride before TURP reduces blood loss and improves early postoperative quality of life.
research Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.
research 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
Baricitinib significantly improves hair regrowth in severe alopecia areata.
research Improvement of female pattern hair loss with bicalutamide: a time-dependent process
Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.
research Paradoxical Skin Reaction to Certolizumab, an Overlap of Pyoderma Gangrenosum and Psoriasis in a Young Woman Treated for Ankylosing Spondylitis: Case Report with Literature Review
A young woman had a rare skin reaction to a medication for her joint disease, and a combination therapy improved her condition.
research Enzalutamide, a prostate cancer therapeutic, downregulates TMPRSS2 in lung and reduces cellular entry of SARS-CoV-2
Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.
research Follicular delivery of a novel peptide therapeutic for the treatment of androgenic alopecia
A new peptide, murikal/SPR4, was found to significantly increase hair growth in mice, and its liposomal topical formulations enhanced hair growth more than commercial products. However, results on human scalp skin were unclear, needing more tests.
research Correction: RASopathic Skin Eruptions during Vemurafenib Therapy
Vemurafenib causes significant skin side effects, requiring regular dermatologist care and sun protection.
research Hub biomarkers in ultrasound-guided bladder cancer and osteosarcoma: Myosin light chain kinase and caldesmon
Lower levels of MYLK and CALD1 in bladder cancer and osteosarcoma are linked to worse survival rates.
research Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: SYNERGY II study
Using mirabegron and solifenacin together is safe and more effective for treating overactive bladder than using either drug alone.
research Abstract ED05-04: Presurgical models to effectively screen preventive agents
Presurgical models can effectively and affordably screen cancer prevention agents.
research Drug Discovery Today: Therapeutic Strategies - 2006 Editorial
The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.